ProChon Biotech Ltd.
This article was originally published in Start Up
Executive Summary
Prochon Biotech believes it has found a key receptor regulating bone growth, and hopes to develop new drugs for bone growth disorders, with an initial focus on achondroplasia, the most common form of human dwarfism.